Tilia Fiduciary Partners’s AbbVie ABBV Stock Holding History

Tilia Fiduciary Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$528K	Hold	2,430	–	–	0.29%	76
2025 Q4	$555K	Sell	2,430 -59	-2%	-$13.4K	0.31%	71
2025 Q3	$576K	Sell	2,489 -180	-7%	-$36.7K	0.33%	68
2025 Q2	$495K	Buy	2,669 +30	+1%	+$5.58K	0.3%	75
2025 Q1	$553K	Sell	2,639 -4	-0.2%	-$778	0.37%	72
2024 Q4	$470K	Sell	2,643 -27	-1%	-$4.96K	0.32%	73
2024 Q3	$527K	Buy	2,670 +127	+5%	+$23.7K	0.37%	66
2024 Q2	$436K	Sell	2,543 -30	-1%	-$4.97K	0.34%	73
2024 Q1	$468K	Buy	2,573 +36	+1%	+$6.2K	0.38%	68
2023 Q4	$393K	Sell	2,537 -132	-5%	-$19.2K	0.37%	74
2023 Q3	$398K	Hold	2,669	–	–	0.41%	67
2023 Q2	$360K	Buy	2,669 +46	+2%	+$6.75K	0.32%	72
2023 Q1	$418K	Hold	2,623	–	–	0.4%	70
2022 Q4	$424K	Hold	2,623	–	–	0.41%	72
2022 Q3	$371K	Hold	2,623	–	–	0.37%	75
2022 Q2	$400K	Buy	2,623 +4	+0.2%	+$611	0.38%	68
2022 Q1	$425K	Buy	2,619 +150	+6%	+$21.8K	0.36%	74
2021 Q4	$334K	Buy	+2,469	New	+$292K	0.27%	82

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tilia Fiduciary Partners's ABBV Position: Q1 2026 in Review

Tilia Fiduciary Partners held its AbbVie (ABBV) position steady in Q1 2026 at 2,430 shares worth $528K. The position accounts for 0.29% of the portfolio, ranked #76.

Tilia Fiduciary Partners first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $576K in Q3 2025. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Tilia Fiduciary Partners held 2,430 shares of AbbVie worth $528K as of Q1 2026.
Tilia Fiduciary Partners left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.29% of Tilia Fiduciary Partners's portfolio in Q1 2026, its #76 holding.
Tilia Fiduciary Partners first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
Tilia Fiduciary Partners's AbbVie position peaked at $576K in Q3 2025.
4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Tilia Fiduciary Partners's 13F filing for Q1 2026, filed 9 Apr 2026.